You are here
Research & Evidence: Tobacco Cessation
Smoking cessation programs work, and we show that covering these programs cost employers little.
Covering Smoking Cessation as a Health Benefit
Milliman: Consultants and Actuaries
Hu,Tian, Seana L. Gall, Rachel Widome, Lydia A. Bazzano, Trudy L. Burns, Stephen R. Daniels, Terence Dwyer, Johanna Ikonen, Markus Juonala, Mika Kähönen, Ronald J. Prineas, Olli Raitakari, Alan R. Sinaiko, Julia Steinberger, Elaine M. Urbina, Alison Venn,. "Childhood/Adolescent Smoking and Adult Smoking and Cessation: The International Childhood Cardiovascular Cohort (i3C) Consortium." Journal of the American Heart Association, April 8, 2020.
Despite declining US adolescent smoking prevalence from 40% among 12th graders in 1995 to around 10% in 2018, adolescent smoking is still a significant problem. Using the International Childhood Cardiovascular Cohort (i3C) Consortium, which includes 7 international cohorts recruited in childhood and followed into adulthood, the present study was designed to confirm the important relation between adolescent smoking and daily adult smoking and present new data on adult smoking into the forties and comparison of smoking in the United States, Finland, and Australia.
Schnoll R, Leone F, Veluz‐Wilkins A,et al. . "A randomized controlled trial of 24 weeks of varenicline for tobacco use among cancer patients: Efficacy, safety, and adherence." Psycho‐Oncology, January 24, 2019.
Continuing to smoke after a cancer diagnosis undermines prognosis. Yet few trials have tested Food and Drug Administration (FDA)‐approved tobacco use medications in this population. Extended use varenicline may represent an effective treatment for cancer patients who smoke given barriers to cessation including a prolonged time line for relapse.
Halpern, Scott D., M.D., Ph.D., Michael O. Harhay, Ph.D., Kathryn Saulsgiver, Ph.D., Christine Brophy, Andrea B. Troxel, Sc.D., and Kevin G. Volpp, M.D., Ph.D.. "A Pragmatic Trial of E-Cigarettes, Incentives, and Drugs for Smoking Cessation." New England Journal of Medicine, June 14, 2018.
BACKGROUND: Whether financial incentives, pharmacologic therapies, and electronic cigarettes (e-cigarettes) promote smoking cessation among unselected smokers is unknown.
CONCLUSIONS: In this pragmatic trial of smoking cessation, financial incentives added to free cessation aids resulted in a higher rate of sustained smoking abstinence than free cessation aids alone. Among smokers who received usual care (information and motivational text messages), the addition of free cessation aids or e-cigarettes did not provide a benefit. (Funded by the Vitality Institute; ClinicalTrials.gov number, NCT02328794.)
Scott Gottlieb, M.D., and Mitchell Zeller, J.D. "A Nicotine-Focused Framework for Public Health." New England Journal of Medicine, August 6, 2017.
Despite extraordinary progress in tobacco control and prevention, tobacco use remains the leading cause of preventable disease and death in the United States. Combustible cigarettes cause the overwhelming majority of tobacco-related disease and are responsible for more than 480,000 U.S. deaths each year. Indeed, when used as intended, combustible cigarettes kill half of all long-term users.
Ralph S. Caraballo, PhD ; Paul R. Shafer, MA ; Deesha Patel ; Kevin C. Davis, MA ; Timothy A. McAfee, MD. "Quit Methods Used by US Adult Cigarette Smokers, 2014–2016." Centers for Disease Control and Prevention, April 13, 2017.
Quitting cigarette smoking greatly reduces the risk of developing smoking-related diseases; although the health benefits are greater for people who stop at earlier ages, there are benefits at any age (1). The use of electronic cigarettes (e-cigarettes) has increased in the United States (2). Little is known about how the rise in e-cigarette use, particularly among current and former adult cigarette smokers, may have affected quitting behaviors. This study assessed common methods used to try to quit cigarettes among a nationally representative online sample of US adult current smokers surveyed from April 2014 through June 2016.
"Coverage for Tobacco Use Cessation Treatments." Centers for Disease Control and Prevention, 2014.
This updated 2014 document provides an overview of the evidence base for tobacco cessation insurance coverage, best practices for designing cessation coverage, and the current status of cessation coverage.
"Best Practices for Comprehensive Tobacco Control Programs ." Centers for Disease Control and Prevention, 201.
Tobacco use is the single most preventable cause of disease, disability, and death in the United States. Nearly one-half million Americans still die prematurely from tobacco use each year, and more than 16 million Americans suffer from a disease caused by smoking. Despite these risks, approximately 42.1 million U.S. adults currently smoke cigarettes. And the harmful effects of smoking do not end with the smoker. Secondhand smoke exposure causes serious disease and death, and even brief exposure can be harmful to health. Each year, primarily because of exposure to secondhand smoke, an estimated 7,330 nonsmoking Americans die of lung cancer and more than 33,900 die of heart disease. Coupled with this enormous health toll is the significant economic burden. Economic costs attributable to smoking and exposure to secondhand smoke now approach $300 billion annually.
Fitch, Kate, RN, MEd; Kosuke Iwasaki, FIAJ, MAAA; Bruce Pyenson, FSA, MAAA. "Covering Smoking Cessation as a Health Benefit." Milliman: Consultants and Actuaries, December 6, 2006.
This report provides information so employers can make informed choices based on the costs and benefits of smoking cessation programs – and compare these to other routinely provided benefits.